This inventor holds 3 USPTO granted patents. Top assignees: Johns Hopkins University, The Wistar Institute. Active years: 2013-2015.
Company Filing History:
3 out of 3,798 
2 out of 246 
Years Active: 2013-2015
Title: The Innovative Contributions of Erin M Bowers
Introduction
Erin M Bowers is a prominent inventor based in Baltimore, MD (US). She has made significant contributions to the field of biomedical research, particularly in the modulation of p300/CBP activity. With a total of 3 patents, her work has the potential to impact cancer treatment and other diseases.
Latest Patents
One of her latest patents is titled "Methods and compositions for modulating P300/CBP activity." This invention relates to a method for identifying compounds that can modulate the activity of p300/CBP. The compounds are identified by designing or screening for a compound that binds to specific amino acid residues of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP. The patent also provides compositions and methods for preventing or treating diseases associated with p300/CBP.
Another significant patent is "Use of histone acetyltransferase inhibitors as novel anti-cancer therapies." This invention outlines methods for treating cancer by inhibiting the activity of p300/CBP histone acetyltransferase (HAT). It includes p300/CBP HAT inhibitors for treating subjects with cancer and biomarkers for monitoring the effectiveness of cancer therapy.
Career Highlights
Erin has worked with esteemed institutions such as Johns Hopkins University and The Wistar Institute. Her research has focused on the mechanisms of histone acetylation and its implications in cancer biology.
Collaborations
Throughout her career, Erin has collaborated with notable scientists, including Philip A Cole and Ronen Marmorstein. These collaborations have enriched her research and contributed to her innovative patents.
Conclusion
Erin M Bowers is a trailblazer in her field, with a focus on developing novel therapies for cancer treatment. Her patents reflect her commitment to advancing biomedical research and improving patient outcomes.